165 terminated. 165 Phase 2, 46 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 165 | Terminated 165 |
| Phase 1 | 46 | Terminated 46 |
| Phase 3 | 3 | Terminated 3 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-08-24 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax Pirtobrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2022-11-16 | 2025-12-15 |
| RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia RP-3500, Olaparib - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | University of Utah | 5 | 2022-09-23 | 2025-06-03 |
| Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL MB-106 - Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent | Phase 1 / Phase 2 | Terminated | Mustang Bio | 20 | 2022-05-24 | 2024-07-22 |
| A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL MS-553 - Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | 13 | 2022-04-28 | 2024-07-18 |
| A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma GLPG5101 - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | Phase 1 / Phase 2 | Terminated | Lakefront Biotherapeutics NV | 130 | 2022-03-09 | 2026-06-30 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 54 | 2021-09-16 | 2026-02-04 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 15 | 2021-06-03 | 2023-03-24 |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT - Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Aprea Therapeutics | 1 | 2021-03-02 | 2025-03-17 |
| Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies ZX-101A - Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | 6 | 2021-02-17 | 2022-10-21 |
| Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy Umbralisib, Ublituximab - Chronic Lymphocytic Leukemia, CLL Progression | Phase 2 | Terminated | Weill Medical College of Cornell University | 1 | 2021-02-10 | 2023-06-15 |
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Daratumumab, Ibrutinib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2020-11-11 | 2025-12-30 |
| Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Acalabrutinib, Rituximab, Ifosfamide - Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 2 | Terminated | University of Miami | 2 | 2020-09-22 | 2025-05-31 |
| Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Duvelisib, Ibrutinib - Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 3 | 2020-07-31 | 2022-03-09 |
| The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide Rituximab, Chemotherapy, Tenofovir alafenamide - Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 5 | 2020-07-07 | 2025-02-27 |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas DTRM-555 - Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Zhejiang DTRM Biopharma | 55 | 2020-04-24 | 2025-01-08 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Copanlisib, Rituximab, Bendamustine - Lymphoid Leukemia, Non-Hodgkin's Lymphoma | Phase 2 | Terminated | University of Washington | 1 | 2020-01-31 | 2022-04-11 |
Showing 20 of 165. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (156) · Lymphoma, Non-Hodgkin (58) · Lymphoma, Follicular (45) · Leukemia (40) · Lymphoma, Mantle-Cell (40) · Lymphoma, Large B-Cell, Diffuse (39) · Lymphoma, B-Cell, Marginal Zone (36) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (36) · Lymphoma (34) · Hodgkin Disease (31) · Leukemia, Myeloid, Acute (28) · Myelodysplastic Syndromes (24) · Multiple Myeloma (23) · Waldenstrom Macroglobulinemia (23) · Recurrence (20)
Hemic and Lymphatic Diseases (165) · Immune System Diseases (165) · Immunoproliferative Disorders (165) · Neoplasms by Histologic Type (165) · Lymphatic Diseases (164) · Leukemia, Lymphoid (162) · Lymphoproliferative Disorders (162) · Hematologic Diseases (159) · Disease Attributes (157) · Pathologic Processes (157) · Pathological Conditions, Signs and Symptoms (157) · Chronic Disease (156) · Neoplasms (154) · Leukemia (125)
Rituximab (37) · Cyclophosphamide (20) · fludarabine phosphate (16) · Antilymphocyte Serum (13) · Lenalidomide (13) · Tacrolimus (13) · Mycophenolic Acid (12) · Methotrexate (10) · umbralisib (10) · Busulfan (9) · fludarabine (9) · Cyclosporine (8) · ublituximab (8) · venetoclax (8) · Melphalan (7)
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (11) · Gilead Sciences (8) · TG Therapeutics, Inc. (8) · H. Lee Moffitt Cancer Center and Research Institute (5) · Masonic Cancer Center, University of Minnesota (5) · Fred Hutchinson Cancer Center (4) · Mayo Clinic (3) · Biogen (2) · Eastern Cooperative Oncology Group (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Januario Castro, M.D. (2) · MingSight Pharmaceuticals, Inc (2) · Northside Hospital, Inc. (2) · OHSU Knight Cancer Institute (2)
United States (138) · Italy (11) · Canada (10) · United Kingdom (10) · France (9) · Belgium (8) · Spain (8) · Poland (7) · Australia (6) · Germany (6) · Austria (5) · China (3) · Czechia (3) · Israel (3) · Netherlands (3)
Januario Castro, M.D. (3) · Thomas J Kipps, M.D., Ph.D. (3) · Anthony Mato, MD (2) · Scott R. Solomon, MD (2) · Steven C. Goldstein, MD (2) · Thomas J. Kipps, M.D., Ph.D. (2) · Adam Petrich, MD (1) · Adrian Bloor (1) · Ajay Gopal (1) · Alessandra Ferrajoli (1) · Alessandra Ferrajoli, MD (1) · Alessandra Ferrajoli, MD,BS (1) · Alessandra Micozzi (1)
PMID 26472751, PMID 34398557, PMID 17579184, PMID 19826119, PMID 20307284, PMID 22289993, PMID 22766223, PMID 23265768, PMID 24241210, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24925211, PMID 24990615, PMID 25130401, PMID 25596730, PMID 25696919, PMID 26183076, PMID 26968534, PMID 27601462, PMID 29141948, PMID 29296805, PMID 30444200, PMID 31217161, PMID 31443741, PMID 31471376, PMID 31723767, PMID 33171487, PMID 33559286, PMID 33683917, PMID 33832946, PMID 37871300, PMID 38517235, PMID 40009495, PMID 41043099, PMID 42660131
P30CA015083 (4), P30CA015704 (3), N01CM17003 (2), P01CA081534 (2), P30CA016058 (2), U10CA021115 (2), 2009 (1), 2015 (1), 2016 (1), 2019 (1), N01CM00070 (1), N01CM62201 (1), N01CM62202 (1), N01CM62204 (1), N01CM62207 (1)